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Abstract
Patients with DYT1 dystonia caused by the mutated TOR1A gene exhibit risk neutral behav-
iour compared to controls who are risk averse in the same reinforcement learning task. It is
unclear whether this behaviour can be linked to changes in cortico-striatal plasticity demon-
strated in animal models which share the same TOR1A mutation. We hypothesised that we
could reproduce the experimental risk taking behaviour using a model of the basal ganglia
under conditions where cortico-striatal plasticity was abnormal. As dopamine exerts oppos-
ing effects on cortico-striatal plasticity via different receptors expressed on medium spiny
neurons (MSN) of the direct (D1R dominant, dMSNs) and indirect (D2R dominant, iMSNs)
pathways, we tested whether abnormalities in cortico-striatal plasticity in one or both of
these pathways could explain the patient’s behaviour. Our model could generate simulated
behaviour indistinguishable from patients when cortico-striatal plasticity was abnormal in
both dMSNs and iMSNs in opposite directions. The risk neutral behaviour of the patients
was replicated when increased cortico-striatal long term potentiation in dMSN’s was in com-
bination with increased long term depression in iMSN’s. This result is consistent with previ-
ous observations in rodent models of increased cortico-striatal plasticity at in dMSNs, but
contrasts with the pattern reported in vitro of dopamine D2 receptor dependant increases in
cortico-striatal LTP and loss of LTD at iMSNs. These results suggest that additional factors
in patients who manifest motor symptoms may lead to divergent effects on D2 receptor
dependant cortico-striatal plasticity that are not apparent in rodent models of this disease.
Introduction
Cortico-striatal plasticity has been implicated in the acquisition and extinction of learned
actions through positive [1] and negative reinforcement learning [2]. Optogenetic studies have
confirmed a causal role for phasic dopamine in the form of the reward prediction error signal
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in determining behavioural choices [3, 4]. This has led to the widely accepted view that dopa-
mine modifies behaviour by mediating its opposing effects on cortico-striatal synaptic strength
via the two principle subtypes of dopamine receptor [5]. Within this framework, phasic
increase in dopamine, which accompanies a rewarding outcome, strengthens the cortico-stria-
tal synapse at Medium Spiny Neurons within the “direct” or striato-nigral pathway (dMSNs).
As this pathway exerts a net facilitatory influence on thalamo-cortical excitability, cortico-
striatal synaptic potentiation in the direct pathway increases the likelihood of this choice being
repeated [6, 7]. Conversely, phasic decreases in dopamine associated with an aversive outcome
lead to a strengthening of cortico-striatal synapses within the “indirect” or striato-pallidal
pathway (iMSNs). As the indirect pathway exerts an inhibitory influence on thalamo-cortical
excitability, the effect of increased cortico-striatal synaptic strengthening at iMSNs is to sup-
press the likelihood of a choice with an aversive outcome being repeated [6, 7]. Both of these
signals rely upon the induction of cortico-striatal long-term potentiation (LTP) at MSNs to
mediate their behavioural effect, albeit under opposite phasic changes in dopamine [8, 9]. The
effects of dopamine on plasticity at the cortico-striatal synapse are in turn mediated by the pre-
dominant expression of D1 (D1R) and D2 (D2R) receptors on MSNs of the direct (dMSN)
and indirect (iMSN) pathways respectively [5, 10]. Accordingly, in humans, individual sensi-
tivity to positive and negative feedback correlates with the extent of D1 or D2 receptor expres-
sion and genetic influences on their variability [11–13].
The mutated TOR1A gene causes generalised dystonia (DYT1), a movement disorder char-
acterised by sustained or intermittent muscle contractions leading to abnormal repetitive
movements and postures [14]. Brain slice recordings of MSNs from rodents expressing the
human mutant gene exhibit abnormal cortico-striatal plasticity with a combination of abnor-
mally strong long term potentiation, LTP [15] and weak long-term depression, LTD [15, 16].
Subsequent studies have delineated a receptor specific abnormality in D2R expression as the
principle cause for impaired LTD at the cortico-striatal synapse in this model [17, 18]. In view
of the importance of cortico-striatal plasticity in reinforcement learning, Arkadir et. al., pro-
posed that patients with the TOR1A mutation should exhibit a learning strategy that is contin-
gent with the abnormal plasticity seen in rodent models [15, 19, 20]. The patients in this study
were found to be significantly more likely to make a risky choice in a reinforcement learning
task compared to controls. They concluded that this risk taking behaviour was consistent with
asymmetric integration of the phasic dopamine signal as a consequence of maladaptive striatal
plasticity. Given the distinct effects that these signals mediate on direct and indirect pathway
excitability, they proposed three possible abnormalities of cortico-striatal plasticity at dMSNs
(D1R dominant) and iMSNs (D2R dominant) that may lead to the pattern of observed behav-
iour: 1) An increased sensitivity to a “win,” due to increased LTP at dMSNs with intact iMSN
plasticity, 2) increased sensitivity to a “win,” with blunted sensitivity to a “loss” both due to
abnormally increased cortico-striatal LTP in dMSNs and increased LTD at iMSN cortico-stria-
tal synapses, 3) increased LTP at cortico-striatal synapses in dMSNs and iMSNs with simulta-
neously blunted LTD at in both types of MSNs. The third explanation was favoured as it was
consistent with the pattern observed from the rodent slice data. This pattern is nevertheless the
most difficult of the three to reconcile with increased risk taking behaviour. If it were the
underlying cause, any increased riskiness mediated by pathological LTP at dMSNs would be
acting in opposition to the risk aversive effects of increased LTP on the excitability of iMSNs.
In this scenario, increased risk taking could therefore only be conferred by an abnormality in
cortico-striatal plasticity in the dMSN population that was substantially greater than that in the
indirect pathway iMSN population.
We wanted to address this conflict between the reported plasticity abnormalities demon-
strated in rodent models and the risk taking behaviour observed in patients using a model of
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cortico-striatal plasticity [21]. In these simulations the model reproduced decision making in
the task whilst being forced to learn under the three proposed conditions of abnormal striatal
plasticity. We found the combination of cortico-striatal plasticity abnormality in dMSN and
iMSN reported from the rodent experiments was least robust for reproducing the actual exper-
imental behaviour of patients. In contrast, the model generated simulated behaviour that was
statistically indistinguishable from that observed experimentally by patients, only when learn-
ing under conditions with the opposite pattern of iMSN cortico-striatal plasticity abnormality
(reduced LTP / increased LTD). We propose this abnormality is easily reconciled with current
understanding of the neurobiology of learning and increased risk taking. Notably, we suggest
that D2R dysfunction may fundamentally differ between dystonically manifest patients and
non-dystonically manifest animal models which share the TOR1A gene mutation.
Methods
Subjects and behavioural paradigm
Behavioural data was from Arkadir et. al., (2016) [19] which included 13 adult patients with
DYT1 dystonia and 13 age and sex-matched controls. All participants gave written informed
consent and the study was approved by the Institutional Review Boards of Columbia Univer-
sity, Beth Israel Medical Center, and Princeton University. Further details regarding patient
medications and clinical assessments are described in detail in the original manuscript. The
trial-and-error (reinforcement) learning task consisted of 326 trial presentations of four
pseudo-letters which served as cues (‘slot machines’). This included an initial familiarisation
(training phase) of 26 trials. Each cue was associated with a different reward schedule (sure 0¢,
sure 5¢, sure 10¢, with the so-called “‘risky” cue associated with 50:50% probabilities of 0¢ or
10¢ payoffs). The task consisted of pseudo-randomised presentations of the cues in either
“forced” or “choice” trials (Fig 1). Pay-out feedback was presented following a “forced” trial
when one of the four cues was presented on its own and selected. During a “choice” trial, feed-
back was given following the subject’s choice of one cue from the pair presented. One of five
pairs of cue combinations were presented during “choice” trials. These included 0¢ versus 5¢,
5¢ versus 10¢, 0¢ versus 0/10¢, 5¢ versus 0/10¢ and 10¢ versus 0/10¢. The principle behavioural
result reported by Arkadir et. al., was an increased tendency for patients to choose the risky
cue when presented with the 5¢ versus 0/10¢ pairing. We therefore focused our re-analysis of
their data on these “risk” choice trials highlighted by Arkadir et. al. To ensure consistency with
their analysis of the task behaviour, we report in an identical fashion, the overall proportion of
risky cue choice both across the task (n = 60 trials) as a whole (Fig 1A) and across four (n = 15
trial) blocks (Fig 1B).
Model fitting
The behavioural data was fitted to the cortico-striatal plasticity (CSP) model described in detail
in Gilbertson et. al. (2019) [21]. This combines a traditional temporal difference (TD) model
of reinforcement learning with biologically plausible cortico-striatal synaptic weight changes
based on in vitro data [5]. At the core of this model are two striatal MSN populations, repre-
senting the direct (dMSN) and indirect (iMSN) pathways, which differ in their dominant
expression of D1R (direct pathway) and D2R (indirect pathway) dopamine receptors. The out-
puts of these pathways are in turn a function of the interaction between the reward prediction
error (RPE) ðRðtÞ   QðA; t   1ÞÞ signal in the equation;
QðA; tÞ ¼ QðA; t   1Þ þ aðRðtÞ   QðA; t   1ÞÞ ð1Þ
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where α is the learning rate, Rt is the outcome (reward[1] or nothing[0]), and the striatal activ-
ity Sn of each population on trial t for action A, which was defined as:
SnðA; tÞ ¼WnðA; t   1Þ � c ð2Þ
whereW is the cortico-striatal synaptic weight and c is a constant input of 1. Each population
SdMSN(dMSNs) and SiMNS (iMSNs) represented four actions (corresponding to the four cue
choices in the task). The cortico-striatal synaptic weights in each population are modified at
the synapse corresponding to the chosen action A;
WnðA; tÞ ¼
WnðA; t   1Þ þ DWnðA; t   1Þ; if WnðA; t   1Þ þ DWnðA; t   1Þ > 0
0; otherwise
ð3Þ
(
With the change in synaptic weight being the product of the striatal postsynaptic activity and
the influence of dopamine:
DWnðA; tÞ ¼ DdnðtÞ � SnðA; tÞ: ð4Þ
Here the magnitude Δdn of dopamine’s effect on synaptic plasticity is:
DdnðtÞ ¼
anðDAðtÞ   yÞ; if DAðtÞ > y
bnðDAðtÞ   yÞ; otherwise
ð5Þ
(
where (an,bn) are coefficients determining the dependence of synaptic plasticity on the current
trial’s level of dopamine DA(t), and the constant θ determines the baseline level of dopamine.
Fig 1. Task. Examples of visual stimuli used in the reinforcement learning task by Arkadir et. al., 2016. Trials were randomly presented as either single stimuli
which required a forced choice and corresponding outcome or as instrumental trials where subjects were instructed to choose one of two of the stimuli. The
risky cue choice trials were between the "risky cue" whose choice led to a 50% chance of 10¢ or 0¢ (highlighted here by the red circle) or the "sure cue" which
had a 100% chance of 5¢ payout.
https://doi.org/10.1371/journal.pone.0226790.g001
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Eq 5 links the RPE from Eq 1 by;
DAðtÞ ¼ DAmin þ
ðRPEðtÞ   RPEminÞDArange
RPErange
ð6Þ
where RPE(t) < 0, DAmin = 0, DArange = θ, RPEmin = −1, RPErange = 1; otherwise DAmin = θ,
DArange = 1 − θ, RPEmin = 0, RPErange = 1.
For forced trials the striatal population’s weightWn(A,t) is updated for the forced action
choice only. During choice trials the model’s chosen action is determined by competition
between the two striatal pathways for control of the pallidal output: see Bariselli et. al., 2018
[22] for a review of the evidence for competition between direct and indirect pathways. The
striatal weights were then updated for the action chosen from the pair of choices. Thus, for a
choice trial with two actions (A1,A2);
GPiðA1; tÞ ¼ ðSdMSNðA1; tÞ   SiMSNðA1; tÞÞHðSdMSNðA1; tÞ   SiMSNðA1; tÞÞ: ð7Þ
whereH() is the Heaviside step function: H(x) = 0 if x� 0, andH(x) = 1 otherwise; and simi-
larly for action A2. In turn the probability of choosing action A1 was determined by the soft-
max equation with the basal ganglia’s output substituted for the value term:
PðA1; tÞ ¼
eðGPiðA1 ;tÞ=bÞ
eðGPiðA1 ;tÞ=bÞ þ eðGPiðA2 ;tÞ=bÞ
: ð8Þ
The CSP model requires estimation of six free parameters. This includes two relating to the
phasic dopamine (RPE) signal, namely the learning rate (α) and reward sensitivity or inverse
temperature parameter (β), and four parameters which govern the magnitude of cortico-stria-
tal plasticity at dMSNs: a1 (LTD) b1 (LTP); and at iMSNs: a2 (LTP), b2 (LTD). Each of these
parameters govern the gradient of the synaptic weight change function and its interaction with
phasic dopamine. Larger values of each parameter lead to more significant changes in synaptic
weight across the dynamic range of dopamine, as this is encoded in the phasic increases and
decreases that index the choice outcomes.
Estimation of the 6 parameters (a1, b1, a2, b2, α, β) was performed simultaneously using
data from the whole task including all trials of both types (forced and choice) and the initial
training phase. We optimised the model parameters by minimising the negative log likelihood
of the data given each parameter combination. This was done using the Matlab (Mathworks,
NA) function fmincon. The initial starting points of this function were estimated following a
grid-search of the parameter space. The bounds of both fmincon and the grid-search were
defined as a1 = [0, 2.5]; b1 = [0, 1.5]; a2 = [-2.5,0], b2 = [-1.5,0], α = [0, 1], β = [0, 2]. (The soft-
max equation in the CSP model divides by β hence the range here has low values relative to
TD models where βmultiplies). The intervals for the grid-search were 0.2, for the “a” parame-
ters, 0.1 for the “b” parameters and 0.1 and 0.2 for α and β respectively due to allow for the dif-
ferences in the ranges of their bounds.
Probability density functions for each of the four plasticity parameters were generated by
fitting a nonparametric kernel function to control subject’s estimates. These were used to
determine the parameter space bounds that defined “pathologically” high (>95%) or low
(<5%) plasticity within the model’s parameter space. For hypotheses testing where cortico-
striatal plasticity was considered to be within the normal “physiological” range, the bounds
were defined by the 5% and 95% confidence limits of the control subject values. Fitting was
then performed separately for each hypothesis (H1-H3) in turn. The combination of dMSN
and iMSN cortico-striatal plasticity abnormalities for each hypothesis were:- “H1” : Increased
dMSN LTP & decreased dMSN LTD; “H2” : Increased dMSN LTP & decreased dMSN LTD,
PLOS ONE Modeling risk taking in DYT1 dystonia
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Decreased iMSN LTP & increased iMSN LTD; “H3” : Increased dMSN LTP & decreased
dMSN LTD, Increased iMSN LTP & decreased iMSN LTD.
Results
Controls
To test the reliability of the final model fitting and its ability to capture healthy control behav-
iour, experimental data sets (n = 1000) were simulated, using the final parameter estimates
(See Table 1 for values). These simulations were generated using the final individual subject
parameters incorporated into the CSP model re-performing the task with the original experi-
mental cue sequence. We compared the simulated model decisions to choose the risky cue to
the choice probabilities from the control subject’s experimental data, by performing a two-way
ANOVA with two independent variables: source of choices [e.g. simulation, experiment],
block number [1–4]. There was no significant difference in the probability of choosing the
risky cue in the experimental behavioural data or the simulated behavioural data (ANOVA, F
(1) = 0.01, p = 0.91), or any difference between the simulated or experimental risky choices
across the four blocks of the tasks (ANOVA [Source, Block], F (3) = 0.4. p = 0.75). For an illus-
trative comparison, the experimental probabilities of choosing the risky cue are plotted in blue
for the controls in Fig 2, with both experimental and simulated choices overlaid in Fig 3. This
analysis suggests that the average choice behaviour between each block in the task could be
simulated using the CSP model for individual controls, and that this was statistically indistin-
guishable from that seen experimentally.
Patients
Re-analysing the experimental data of Arkadir et al., we found the same tendency for patients
to show significantly less risk aversion (Fig 2A), although choosing the risky stimulus signifi-
cantly more often than controls (DYT 0.44 ± 0.04, CTL 0.26 ± 0.05, Mann-Whitney z = 2.23,
df = 24, P< 0.05). Importantly, the patients increased risky decision taking continued
throughout the four experimental blocks (conducting a one-way ANOVA with task block as a
single independent variable, indicating no significant effect of block, F (1) = 0.62, p = 0.61).
Notably the choice of the risky cue led to a 50:50% probability of either 0 or 10$ outcome, so
this absence of any modification of risk taking behaviour over time was despite receiving pro-
portionately more 0$ (losing) outcomes (Fig 2B). Our aim of fitting the patient’s behaviour
data was therefore to capture both the overall level of riskiness across the task and this absence
of risky cue devaluation between blocks. We therefore re-fitted the patient’s behavioural data
whilst constraining the bounds of the fitting procedure to the parameter space defined by the
three hypothesised plasticity combinations (H1-H3). As all three hypothesis shared an increase
in dMSN cortico-striatal LTP in common, each individual hypothesis was aimed at testing dif-
ferent contributions of iMSN cortico-striatal plasticity for risk taking. For “H1” Increased
dMSN LTP was accompanied by physiological (control) levels of iMSN cortico-striatal
Table 1. Final model parameter estimates.
Cortico-striatal plasticity parameters Temporal difference parameters
dMSN LTD (a1) dMSN LTP (b1) iMSN LTP (a1) iMSN LTD (b2) α β
Patients (H1) 0.21±0.01 1.45±0.01 -1.69±0.16 -0.92±0.15 0.72±0.07 0.09 0.06
Patients (H2) 0.19±0.02 1.47±0.03 -0.38±0.015 -1.55±0.023 0.53±0.09 0.14±0.03
Patients (H3) 0.15±0.017 1.45±0.01 -2.44±0.01 -0.31±0.02 0.80±0.07 0.10±0.01
Controls 1.42±0.24 1.02±0.09 -1.44 ±0.22 -1.07±0.12 0.34 ±0.1 0.09 ±0.01
https://doi.org/10.1371/journal.pone.0226790.t001
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plasticity. For “H2” iMSN cortico-striatal plasticity was opposite to that for dMSNs and baised
towards excess LTD. Finally, for “H3” the increase in dMSN LTP was accompanied by a paral-
lel increase in LTP at iMSN cortico-striatal synapses. Comparing the individual negative log
likelihoods of each hypothesis demonstrated a trend towards H1 and H2 (10 subjects) explain-
ing the behaviour better than H3 (Fisher exact test χ2 (24) = 11.1, p = 0.05 Bonferroni cor-
rected), but no overall single wining hypothesis. Given the similarity of both the negative log
likelihood values and the overlap between the hypothetical plasticity abnormalities, we tested
whether any one of the hypothesis could recover the risky choice behaviour by comparing
their simulated (generated) risk taking behaviour. We generated simulated “experiments”
(n = 1000) using individual patient parameter estimates for each hypothesis. The results are
plotted alongside the simulated and experimental control data in Fig 3. As illustrated (Fig 3B)
the only hypothesis, which could accurately recover the experimental behaviour, was H2 with
LTP increased at dMSNs and LTD increased at iMSN cortico-striatal synapses. A feature of
the alternative hypotheses (H1 & H3) was their inability to capture the between-block risk tak-
ing behaviour of the patients which remained relatively similar across the whole task (i.e. from
blocks 1–4 the risky cue was chosen to a similar degree). In contrast, when the model per-
formed the task with the predefined plasticity abnormalities associated with H1 & H3, the
models choice probability of the risky cue substantially reduced between the beginning (block
1) and end of the task (block 4).
Statistically, this observation was reflected by there being no discernible difference between
the simulated models risky cue choice, under H2’s plasticity conditions, and the experimental
patient’s risky cue choice probability. A two-way ANOVA with two independent variables
(source of choices [simulation or experiment], task block) indicated there was no effect of the
source of the choice data (ANOVA, F (1) = 0.44, p = 0.50) or any significant interaction
Fig 2. Experimental risk taking behaviour in patients and controls. (A) Boxplots illustrate the mean choice probability of the patients (red) and controls
(blue) represented by the horizontal lines across the task as a whole. Each individual subjects choice probabilities are superimposed. The grey boxes represent
the interquartile range. (B) The patients and controls average choice probabilities across four 15 trial blocks over the course of the task. The error bars represent
the S.E.M. � Mann-Whitney z = 2.33, P< 0.05.
https://doi.org/10.1371/journal.pone.0226790.g002
PLOS ONE Modeling risk taking in DYT1 dystonia
PLOS ONE | https://doi.org/10.1371/journal.pone.0226790 May 4, 2020 7 / 15
between the variables (ANOVA, F(3) = 1.48, p = 0.21). Consistent with the experimental
choice behaviour in the patients, there was no statistically significant between-block differ-
ences in choice probability for the simulations under H2’s plasticity conditions (ANOVA, F(3)
Fig 3. Simulated risk taking under each hypothetical plasticity abnormality. Each plot from A-C illustrates the final
average synaptic weight change curve for the patients under each hypothetical plasticity condition (H1-H3). See text
for details of the dMSN and iMSN plasticity abnormality for each hypothesis. The average simulated (n = 1000
simulations) choice probability of the risky cue for each block (1–4) in the task is represented by the dashed (—) lines
with the patients in red and controls in blue. The error bars represent the average standard error across the simulated
experiments. The solid lines (-) represent the average choice (±S.E.M) from the experimental data of Arkadir et. al.
(2016). Significant differences between the simulated and experimental mean choice probability were present under
plasticity conditions for H1 (�p = 0.01) and H3 (��p<0.001) but not for H2, consistent with the overlapping
experimental and simulated choices for this hypothesis.
https://doi.org/10.1371/journal.pone.0226790.g003
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= 1.99, p = 0.12). In contrast, there was a significant difference in the simulated decision mak-
ing of the model under the plasticity conditions of H1 and H3. For both hypotheses there was
a significant interaction between the variables for H1 (ANOVA, F (3) = 3.63, p = 0.01) and H3,
(ANOVA, F (3) = 32.12, p<0.001). Furthermore, there was also an effect of block for both
hypotheses, H1, (ANOVA, F(3) = 5.46, p<0.01), H3 (ANOVA, F(3) = 43.49, p<0.001). The
choice probability across the task for both of these models therefore contrasted with, and did
not capture, the experimental patient behaviour where no statistical difference was detected
between each block of the task (see above). In all, this analysis would support the assertion that
the only hypothesis that could accurately reproduce both the risk neutral behaviour of the
patients and their behaviour between blocks across the task, was one where LTP was increased
in dMSNs in combination with increased LTD at iMSN cortico-striatal synapses. The reliabil-
ity of the model under the plasticity conditions of H2 to replicate the experimental behaviour
is further illustrated in Fig 4A. Here we plot a single simulated experiment and for illustrative
proposes, a random sample of 100 (from the 1000 generated) simulated control and dystonia
behavioural experiments.
Consistent with the constraints on the fitting procedure for H2, where all four parameters
were in the “pathological” range, the final plasticity parameters fitted to the patients (a1-b2) were
all significantly different from the healthy controls (Two-way ANOVA (F(3) = 30, p<0.001). In
contrast, there was no corresponding difference in the α (Mann-Whitney z (24) = 1.2, p = 0.23),
or β terms (Mann-Whitney z (24) = 1.2, p = 0.22). The final dopamine weight change curve for
patients (H2) and controls illustrates the expected effects of dopamine in the presence of
increased D1R mediated dMSN LTP to LTD and decreased D2R mediated LTP to LTD at iMSN
cortico-striatal synapses (Fig 5). Relative to controls, patients significantly strengthened the direct
pathway (dMSN’s) and weakened the cortico-striatal synaptic connection in the indirect pathway
(iMSN) in response to a phasic increase in dopamine. Conversely, when dopamine levels are
Fig 4. Simulated choices under plasticity conditions for H2. Example of a single simulated experiment using the final parameters estimates for the controls and
patient estimates with H2 (A). This captures both the experimental mean and individual variance in both groups and closely replicates the experimental
behaviour The CSP model was robust in replicating this behaviour across multiple simulations (B). For illustrative purposes we plot the first 100 of the 1000
simulated data sets from both the individual controls (blue) and patients (red). The mean choice of the risky cue and interquartile range (average between
simulations) are represented by the dashed blue and solid red cross-hairs in the controls and patients respectively.
https://doi.org/10.1371/journal.pone.0226790.g004
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reduced below baseline levels following a loss, less LTP is produced at the cortico-striatal synapse
in the models iMSNs and less LTD in the dMSN population. The behavioural consequences of
these changes are for the model to choose the risky choice more frequently.
To understand why the CSP model could only recover the behaviour of the patients when
cortico-striatal plasticity was abnormal in both groups of MSNs in opposite directions, we
examined the time course of changes in D1 and D2R mediated cortico-striatal plasticity within
the dMSN and iMSN populations in the model through the task. These are illustrated for H1 &
H2 in Fig 5A and 5B. As expected for a striatum where the cortico-striatal synapse at dMSNs
undergo greater LTP in response to a phasic increase in dopamine, the synaptic weight repre-
senting the risky cue in the patients increases rapidly to strengths that significantly exceed
those of the controls in both models. In contrast, the cortico-striatal synaptic strength in the
iMSNs, predominantly expressing the D2R, remains unchanged in the H2 model relative to
the controls. At first glance, this seems counter intuitive given that H2 includes impaired
iMSN cortico-striatal LTP (and increased LTD relative to LTP), however, this lack of build-up
iMSN synaptic weight is pathological and reflects the blunted plasticity response to phasic
reductions in dopamine that follow a risky “loss”. This can be understood when the iMSN syn-
aptic weight changes are compared between the H1 (Fig 6A) and H2 (Fig 6B) models. Under
conditions of intact cortico-striatal plasticity at iMSNs, the H1 model generates a substantial
increase in iMSN synaptic weight and activity in the indirect pathway. This is proportionate to
the increased risky choices and the inevitable phasic reductions in dopamine that follow risky
choices were the outcome is worse than expected. In contrast, in the presence of excessive
LTD at cortico-striatal synapses in iMSNs under ‘H2’ plasticity conditions, there is no corre-
sponding increase in indirect pathways weights. At a behavioural level this is indexed by no
time dependent devaluation of the risky cue between blocks. This difference between the two
Fig 5. Final dopamine-synaptic weight change for patients and controls. Solid lines, D1R, dashed lines D2R. Mean
values ± S.E.M represented by shaded area. Patients in red, controls in blue.
https://doi.org/10.1371/journal.pone.0226790.g005
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models suggests that for the combination of reduced risk aversion and reduced choice devalua-
tion observed in the DYT1 patients, cortico-striatal plasticity needs to be abnormal in oppos-
ing directions in both populations of dMSN and iMSNs of the direct and indirect pathways
simultaneously.
Fig 6. Simulated striatal synaptic weight changes during the task for the risky cue. Average simulated weights ± S.E.
M (between simulations) for the CSP model under plasticity conditions of H1 (A) and H2 (B). Weights representing
the risky cue are illustrated only. Cortico-striatal iMSN (D2R dependant) weights, dashed lines (—) dMSN (D1R
dependant) cortico-striatal weights, solid lines (-). Patients in red, controls in blue.
https://doi.org/10.1371/journal.pone.0226790.g006
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Discussion
Animal models for rare and devastating neurological diseases such as DYT1 dystonia are a
central pillar to the development of the therapeutic armamentarium. Their relevance to the
disease however requires close scrutiny and validation of experimental data across disciplines
in order to maximise their translational potential. The purpose of the present study was aimed
at reconciling recent experimental observations of risk neutral learning in patients with the
TOR1A mutation [19] and reports of excess cortico-striatal LTP and diminished LTD in the
established rodent genetic model of this disease [15]. To address this question, we used a com-
puter model of the basal ganglia with detailed cortico-striatal plasticity which re-performed
the same reinforcement learning task studied experimentally by Arkadir et. al (2016). This
model was able to generate simulated choices that were statistically identical to those obtained
experimentally in both the patient and control groups. Critical to the purpose of our study,
was that the model was unable to reproduce the experimental behaviour of the patients when
the pattern of plasticity abnormalities identified in the TOR1A rodents were incorporated into
the model (our ‘H3’–increased cortico-striatal LTP in both dMSN and iMSNs.). Only when
the opposite pattern of cortico-striatal plasticity at iMSNs, (‘H2’ increased dMSN LTP and
iMSN LTD), was the patients risk neutral choices replicated.
There are several limitations to our approach which necessitate caution when interpreting this
result given that it conflicts the animal literature. Firstly, in order to capture the heuristic dynam-
ics of synaptic plasticity at the cortico-striatal synapse, we reduced the mechanics of this process
to a level of abstraction (four parameters) which makes direct comparison to in vitromeasure-
ments unclear. We cannot therefore make a meaningful quantitative comparison between our
dopamine weight change curve (Fig 5) and the neurophysiological measurements from in vitro
data. Reducing the biophysical detail of our model was necessary to avoid over fitting and allow
meaningful hypothesis testing of the parameters of interest (in our case those relating to cortico-
striatal plasticity). We cannot discount the possibility that assumptions of our model such as con-
stant levels of tonic dopamine or omitting detailed cholinergic influence on iMSN cortico-striatal
LTD [23] may have influenced our results. Future studies will be need to address whether these
details are significant in determining the model’s ability to replicate risky decision making.
Despite these limitations, there are several reasons to consider that the opposite iMSN plasticity
abnormality to that seen in the animal data best explains the patient’s behaviour. Firstly, the pro-
pensity to make risky choices can be considered a consequence of an enhanced sensitivity to
reward following a successful risky choice, combined with blunted sensitivity to choices that lead to
an aversive outcome. If the same increase in iMSN cortico-striatal LTP in the rodent model were
manifest in the patients studied by Arkadir et. al., (2016), this would be expected to make them
more risk averse by generating greater iMSN LTP following a risky choice which resulted in a los-
ing outcome. In turn, this would raise the excitability of the indirect pathway and due to its net
inhibitory influence on thalamo-cortical excitability, would suppress the likelihood of the risky cue
being re-chosen. As optogenetic induction of cortico-striatal LTP in dMSNs leads to risk seeking
[24] and iMSNs stimulation leads to risk aversion [25], the parallel increases in cortico-striatal LTP
identified in both dMSN and iMSNs in TOR1A rodents would be expected to act antagonistically
and nullify their overall effect on risk taking. This interpretation is supported by the results of our
simulations as illustrated by the significant between block (Fig 3C ‘H3’) reduction in risky choices
by the model with increased iMSN LTP, to risk taking levels comparable to that of the controls.
This was neither a feature of the patient’s experimental data or the simulated choices under model
conditions of increased iMSN LTD (‘H2’). Our simulations provide further evidence that increased
LTP in dMSNs in combination with the opposite abnormality at iMSNs, of increased cortico-stria-
tal LTD, is the most parsimonious explanation for the patient’‘s risk neutral behaviour.
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Impaired generation of LTP at iMSN cortico-striatal synapses following a risky “loss” is in
the DYT1 patients is also analogous to the loss of iMSN LTP and increased LTD in a model of
impaired reversal learning seen in patients with cervical dystonia [21]. These results support a
common mechanism of deficient LTP and excess LTD at iMSN cortico-striatal synapse’s caus-
ing abnormal reinforcement learning that is independent of the specifics of the task or dysto-
nia phenotype. As the density of D2R correlates with the sensitivity to negative decision
outcomes [12, 13] the loss of cortico-striatal LTP at iMSN synapses is also consistent with
imaging studies demonstrating reduced D2R in both forms of dystonia [26, 27].
The discrepancy between the human and rodent cortico-striatal iMSN plasticity abnormalities
predicted by our simulations and those demonstrated in rodent models of DYT1 dystonia have
crucial implications for our understanding of this condition and the development of new therapies
for patients. In the first instance, they support the idea that striatal neurochemistry is not indifferent
to dystonically manifest and non-manifest behavioural states. Notably, although animals with the
TOR1A mutation have significant striatal neurochemical abnormalities, they exhibit little to no phe-
notypic resemblance of a movement disorder. It is conceivable therefore, that a reason for our results
supporting an opposite pattern of abnormal plasticity at iMSNs to that seen in vitro, reflects a dif-
ference between the manifesting dystonic and non-manifesting states. This explanation is sup-
ported by observations from previous studies. First, following the peripheral nerve injury necessary
to induce dystonia-like posturing in TOR1A mutant rodents, these are accompanied by significant
increases in striatal dopamine and decreases in D2R receptor expression [28].This fundamental
shift in dopaminergic neurochemistry has also been observed in recent post mortem studies com-
paring manifesting and non-manifesting carriers of the TOR1Amutant gene [29]. Second, the
study of Edwards et. al., (2006) [30] emphasises the apparent paradox of how the same mutation
can lead to an opposite physiological response depending on the clinically manifest state. Here
TOR1A mutation carriers were tested using transcranial magnetic simulation protocols which
induced LTD-like plasticity in healthy controls. These failed to induce any response in non-mani-
festing carriers but produced an exaggerated LTD-like response in the manifesting carriers.
Given this context it is unsurprising that our computational modelling of patient’s behav-
iour converges on a conclusion opposite to that reported from experiments using animal mod-
els of human DYT1 dystonia. Our results have important implications for the development of
small molecular therapies based on translational studies in rodents [31]. We argue that since
performance on reinforcement learning tasks correlates with the severity of the movement dis-
order in these patients, these tasks could be used to screen putative therapeutic agents based
upon their ability to modify reward learning. This would be a cost effective intermediate step
prior to formal clinical trial testing aimed to at the identification of novel agents.
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